A spent nuclear fuel transportation container. (Photo: DOE)
Fusion systems company SHINE Technologies has notified the Nuclear Regulatory Commission that it intends to submit a license application to build and operate a pilot used nuclear fuel recycling facility.
SHINE Technologies founder and CEO Greg Piefer shows the hot cell banks that will be used to produce Lu-177. (Image: SHINE)
Fusion tech company SHINE Technologies announced that it is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used in targeted cancer therapies.
SHINE’s Mo-99 production building under construction in October 2022. (Photo: SHINE)
Fusion development company SHINE Technologies announced that it will begin offering radiation effects testing in a dedicated facility on the company’s Janesville, Wis., campus later this year. SHINE will use high-energy fusion neutrons to test mission-critical components that are susceptible to radiation-harsh environments on behalf of its aerospace and defense customers.
The electron accelerator that will be used for Mo-99 production at NorthStar’s newly completed facility in Wisconsin. (Photo: NNSA)
NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wis., to produce the medical radioisotope molybdenum-99 without the use of high-enriched uranium, the Department of Energy’s National Nuclear Security Administration announced last week.
A rendering of the SHINE medical isotope production facility planned for construction in Veendam, the Netherlands. (Image: SHINE)
SHINE Europe, a subsidiary of Wisconsin-based SHINE Technologies, will work with the Netherlands’ University Medical Center Groningen (UMCG) and Delft University of Technology (TU Delft) to produce a variety of terbium isotopes for use in nuclear medicine under a grant proposal approved by the Dutch government on October 17.
SHINE’s Mo-99 production facility under construction in Janesville, Wis. (Photo: SHINE)
SHINE Europe, a nascent subsidiary of Wisconsin-based SHINE Technologies, announced Wednesday that it has secured funding to begin designing an advanced medical isotopes facility in Veendam, the Netherlands. The new facility will use the same fusion-based neutron generator system SHINE is employing at its Janesville, Wis., facility to produce medical isotopes, including molybdenum-99, which is used in diagnostic imaging.
SHINE Technologies’ headquarters building in Janesville, Wis. (Photo: SHINE)
The Department of Energy’s National Nuclear Security Administration has issued a cooperative agreement worth $35 million to SHINE Technologies, based in Janesville, Wis., to support the commercial production of molybdenum-99, a critical isotope used in more than 40,000 medical procedures in the United States each day, including the diagnosis of heart disease and cancer.
A rendering of the SHINE medical isotope production facility planned for construction in Veendam, the Netherlands. (Image: Shine)
SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.
SHINE executives, construction managers, and partners commemorate a construction milestone of the medical isotope production facility in March. (Photo: SHINE)
The Nuclear Regulatory Commission has approved a request by SHINE Medical Technologies for an exemption from regulations on how commercial grade equipment is defined, allowing the company to more easily procure components for the medical isotope production facility it is building in Janesville, Wis.
NorthStar is capable of producing Mo-99 using non-uranium-based processes. Photo: NorthStar Medical Radioisotopes
Completing a 5,700-mile journey from Belgium, two 24-ton particle accelerators were delivered to NorthStar Medical Radioisotopes’ facility in Beloit, Wis., on April 22, the Wisconsin State Journal reported. Photos and a video of the accelerators being received at the facility are included in the report.